Published online before print December 6, 2004, doi: 10.1161/01.CIR.0000150539.72783.BF
(Circulation. 2004;110:3815-3821.)
© 2004 American Heart Association, Inc.
Molecular Cardiology |
Detection of Cardiac Allograft Rejection and Response to Immunosuppressive Therapy With Peripheral Blood Gene Expression
From the Department of Internal Medicine, Division of Cardiovascular Diseases, University of Iowa–Roy J. and Lucille A. Carver College of Medicine (P.A.H.), Iowa City, Iowa; Department of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania School of Medicine (E.J.T., J.M.G., J.J.L., M.S.P., A.C.K., S.S.D., L.R.G., S.C.B., M.L.J., J.A.E., T.P.C.), Philadelphia, Pa; and Division of Biostatistics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania (M.E.P.), Philadelphia, Pa.
Correspondence to Thomas P. Cappola, MD, ScM, Heart Failure and Transplantation, Division of Cardiovascular Medicine, 6 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104. E-mail thomas.cappola{at}uphs.upenn.edu
Received June 29, 2004; revision received September 28, 2004; accepted October 15, 2004.
Background— Assessment of gene expression in peripheral blood may provide a noninvasive screening test for allograft rejection. We hypothesized that changes in peripheral blood expression profiles would correlate with biopsy-proven rejection and would resolve after treatment of rejection episodes.
Methods and Results— We performed a case-control study nested within a cohort of 189 cardiac transplant patients who had blood samples obtained during endomyocardial biopsy (EMB). Using Affymetrix HU133A microarrays, we analyzed whole-blood expression profiles from 3 groups: (1) control samples with negative EMB (n=7); (2) samples obtained during rejection (at least International Society for Heart and Lung Transplantation grade 3A; n=7); and (3) samples obtained after rejection, after treatment and normalization of the EMB (n=7). We identified 91 transcripts differentially expressed in rejection compared with control (false discovery rate <0.10). In postrejection samples, 98% of transcripts returned toward control levels, displaying an intermediate expression profile for patients with treated rejection (P<0.0001). Cluster analysis of the 40 transcripts with >25% change in expression levels during rejection demonstrated good discrimination between control and rejection samples and verified the intermediate expression profile of postrejection samples. Quantitative real-time polymerase chain reaction confirmed significant differential expression for the predictive markers CFLAR and SOD2 (UniGene ID No. 355724 and No. 384944).
Conclusions— These data demonstrate that peripheral blood expression profiles correlate with biopsy-proven allograft rejection. Intermediate expression profiles of treated rejection suggest persistent immune activation despite normalization of the EMB. If validated in larger studies, expression profiling may prove to be a more sensitive screening test for allograft rejection than EMB.
Key Words: immune system • transplantation • rejection • genes • diagnosis
Related Article:
Circulation 2004 110: 3743.
This article has been cited by other articles:
 |
|
 |
|
  Y. Bosse, P. Mathieu, and P. Pibarot Genomics: The Next Step to Elucidate the Etiology of Calcific Aortic Valve Stenosis J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1327 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Z. Sulemanjee, R. Merla, S. D. Lick, S. M. Aunon, M. Taylor, M. Manson, L. S.C. Czer, and E. R. Schwarz The First Year Post-Heart Transplantation: Use of Immunosuppressive Drugs and Early Complications Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 13 - 31. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Li, L. Ying, M. Naesens, W. Xiao, T. Sigdel, S. Hsieh, J. Martin, R. Chen, K. Liu, M. Mindrinos, et al. Interference of globin genes with biomarker discovery for allograft rejection in peripheral blood samples Physiol Genomics, January 17, 2008; 32(2): 190 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. U. Nwakanma, A. S. Shah, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1539 - 1578. [Full Text]
|
|
|
|
|
|
G. S. Ginsburg, D. Seo, and C. Frazier Microarrays Coming of Age in Cardiovascular Medicine: Standards, Predictions, and Biology J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1618 - 1620. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hannenhalli, M. E. Putt, J. M. Gilmore, J. Wang, M. S. Parmacek, J. A. Epstein, E. E. Morrisey, K. B. Margulies, and T. P. Cappola Transcriptional Genomics Associates FOX Transcription Factors With Human Heart Failure Circulation, September 19, 2006; 114(12): 1269 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Seo, G. S. Ginsburg, and P. J. Goldschmidt-Clermont Gene Expression Analysis of Cardiovascular Diseases: Novel Insights Into Biology and Clinical Applications J. Am. Coll. Cardiol., July 18, 2006; 48(2): 227 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zheng, Y. Luo, and G. K. McMaster Sensitive and Quantitative Measurement of Gene Expression Directly from a Small Amount of Whole Blood Clin. Chem., July 1, 2006; 52(7): 1294 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Podgoreanu and D. A. Schwinn New Paradigms in Cardiovascular Medicine: Emerging Technologies and Practices: Perioperative Genomics J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1965 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Ginsburg, M. P. Donahue, and L. K. Newby Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Liang and B. Ventura Physiological genomics in PG and beyond: July to September 2005 Physiol Genomics, October 17, 2005; 23(2): 119 - 124. [Full Text] [PDF]
|
|